Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Q: What are the significant segments operating in the market?

Market is segmented on the basis. Read More

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID : 103297
Published On: Mar, 2022
Pages: 156
Pharmaceuticals and Healthcare

Buy @ $3500

The Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is estimated to be worth US$ 7854.6 million in 2021 and is forecast to a readjusted size of USD 11030 million by 2028 with a CAGR of 5.0% during review period. Hospitals & Clinics accounting for % of the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Oral Therapy segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation, and Bayer AG, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Oral Therapy

Injectable Therapy

Market segment by Application, can be divided into

Hospitals & Clinics

Home Settings

Ambulatory Surgical Centers (ASCs)

Market segment by players, this report covers

Astellas Inc.

Johnson & Johnson

Sanofi S.A

Dendreon Corporation

Bayer AG

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics, with revenue, gross margin and global market share of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics from 2019 to 2022.

Chapter 3, the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics research findings and conclusion, appendix and data source.

Frequently Asked Questions

What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

What are the significant segments operating in the market?

Market is segmented on the basis:

By Type
By Application
By Region
By Country
By Manufacturer

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics

1.2 Classification of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type

1.2.1 Overview: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2021

1.2.3 Oral Therapy

1.2.4 Injectable Therapy

1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market by Application

1.3.1 Overview: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals & Clinics

1.3.3 Home Settings

1.3.4 Ambulatory Surgical Centers (ASCs)

1.4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size & Forecast

1.5 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast by Region

1.5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region, (2017-2022)

1.5.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2017-2028)

1.5.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2017-2028)

1.5.6 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers

1.6.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints

1.6.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Trends Analysis

2 Company Profiles

2.1 Astellas Inc.

2.1.1 Astellas Inc. Details

2.1.2 Astellas Inc. Major Business

2.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

2.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Astellas Inc. Recent Developments and Future Plans

2.2 Johnson & Johnson

2.2.1 Johnson & Johnson Details

2.2.2 Johnson & Johnson Major Business

2.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

2.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Johnson & Johnson Recent Developments and Future Plans

2.3 Sanofi S.A

2.3.1 Sanofi S.A Details

2.3.2 Sanofi S.A Major Business

2.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

2.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Sanofi S.A Recent Developments and Future Plans

2.4 Dendreon Corporation

2.4.1 Dendreon Corporation Details

2.4.2 Dendreon Corporation Major Business

2.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

2.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Dendreon Corporation Recent Developments and Future Plans

2.5 Bayer AG

2.5.1 Bayer AG Details

2.5.2 Bayer AG Major Business

2.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

2.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Bayer AG Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share in 2021

3.2.2 Top 10 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Head Office, Products and Services Provided

3.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Mergers & Acquisitions

3.5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Market Share by Type (2017-2022)

4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application (2017-2022)

5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2028)

6.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2028)

6.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country

6.3.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2028)

6.3.2 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2028)

7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2028)

7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country

7.3.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2028)

7.3.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

7.3.3 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

7.3.5 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

7.3.6 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2028)

8.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2028)

8.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region

8.3.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2017-2028)

8.3.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8.3.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8.3.4 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8.3.5 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

8.3.7 Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2028)

9.2 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2028)

9.3 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country

9.3.1 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2028)

9.3.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

9.3.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2028)

10.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2028)

10.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country

10.3.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2028)

10.3.2 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

10.3.4 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Region (2017-2022)

Table 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2023-2028)

Table 6. Astellas Inc. Corporate Information, Head Office, and Major Competitors

Table 7. Astellas Inc. Major Business

Table 8. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

Table 9. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 11. Johnson & Johnson Major Business

Table 12. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

Table 13. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Sanofi S.A Corporate Information, Head Office, and Major Competitors

Table 15. Sanofi S.A Major Business

Table 16. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

Table 17. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Dendreon Corporation Corporate Information, Head Office, and Major Competitors

Table 19. Dendreon Corporation Major Business

Table 20. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

Table 21. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Bayer AG Corporate Information, Head Office, and Major Competitors

Table 23. Bayer AG Major Business

Table 24. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions

Table 25. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 27. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 28. Breakdown of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)

Table 29. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Head Office, Products and Services Provided

Table 30. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Mergers & Acquisitions in the Past Five Years

Table 31. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics New Entrants and Expansion Plans

Table 32. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Type (2017-2022)

Table 33. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type (2017-2022)

Table 34. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Type (2023-2028)

Table 35. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022)

Table 36. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Application (2023-2028)

Table 37. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 38. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 39. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 40. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 41. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 42. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 43. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 44. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 45. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 46. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 47. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 48. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 49. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 50. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 51. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 52. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 53. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2017-2022) & (USD Million)

Table 54. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2023-2028) & (USD Million)

Table 55. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 56. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 57. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 58. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 59. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 60. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2023-2028) & (USD Million)

Table 61. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2017-2022) & (USD Million)

Table 62. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2023-2028) & (USD Million)

Table 63. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2017-2022) & (USD Million)

Table 64. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2023-2028) & (USD Million)

Table 65. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2017-2022) & (USD Million)

Table 66. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Picture

Figure 2. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2021

Figure 3. Oral Therapy

Figure 4. Injectable Therapy

Figure 5. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application in 2021

Figure 6. Hospitals & Clinics Picture

Figure 7. Home Settings Picture

Figure 8. Ambulatory Surgical Centers (ASCs) Picture

Figure 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Forecast (2017-2028) & (USD Million)

Figure 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2017-2028)

Figure 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region in 2021

Figure 13. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers

Figure 19. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints

Figure 20. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends

Figure 21. Astellas Inc. Recent Developments and Future Plans

Figure 22. Johnson & Johnson Recent Developments and Future Plans

Figure 23. Sanofi S.A Recent Developments and Future Plans

Figure 24. Dendreon Corporation Recent Developments and Future Plans

Figure 25. Bayer AG Recent Developments and Future Plans

Figure 26. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players in 2021

Figure 27. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 28. Global Top 3 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2021

Figure 29. Global Top 10 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2021

Figure 30. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 31. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type in 2021

Figure 32. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Type (2023-2028)

Figure 33. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Application in 2021

Figure 34. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Application (2023-2028)

Figure 35. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2017-2028)

Figure 36. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2017-2028)

Figure 37. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2017-2028)

Figure 38. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 39. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 40. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 41. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2017-2028)

Figure 42. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2017-2028)

Figure 43. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2017-2028)

Figure 44. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 45. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. United Kingdom Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2017-2028)

Figure 50. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2017-2028)

Figure 51. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2017-2028)

Figure 52. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2017-2028)

Figure 59. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2017-2028)

Figure 60. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2017-2028)

Figure 61. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2017-2028)

Figure 64. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2017-2028)

Figure 65. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2017-2028)

Figure 66. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Methodology

Figure 70. Research Process and Data Source

License Type

Quick Contact

Our Clients

Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz